Amniotic Membrane for Recurrent Macular Hole

The Safety and Efficacy of Using Amniotic Membrane for Closure of Recurrent Macular Hole

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03528122

Enrollment

Registered

2018-05-17

Start date

2018-02-01

Completion date

2020-05-01

Last updated

2020-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macula Hole, Myopic Macular Degeneration, Retinal Detachment

Keywords

amniotic membrane, retinal detachment, Myopic, macular hole, internal limiting membrane

Brief summary

Macular hole surgery were tried by different surgeons using many techniques with different successes but still there were many recurrences. In this study the investigators try to close these distinct types including recurrent holes using pre-prepared amniotic membrane.

Detailed description

It is an interventional study of using amniotic membrane graft for closure of macular hole associated retinal detachment in patient who had a previous failed macular surgery.

Interventions

PROCEDURERecurrent opened macular hole

pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Individuals with recurrent macular hole associated retinal detachment

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patient with history of opened macular hole after previous pars plana vitrectomy and internal limiting membrane (ILM) peeling for treatment of myopic macular hole were included. * Opened holes after 1 month of the surgery. * Myopic macular holes only were included (Refraction of more than \_6 D and/or axial length of more than 26 mm).

Exclusion criteria

* All other causes of macular hole (traumatic and idiopathic) * Patients with diseases that can affect visual outcome (Diabetic retinopathy, choroidal neovascularization, age-related macular disease and advanced glaucoma patients.

Design outcomes

Primary

Measure	Time frame	Description
Anatomical restoration of macular hole closure	6 months	Closure of the macular hole

Secondary

Measure	Time frame	Description
Functional restoration after closure of the macular hole	6 months	Improvement of the best corrected visual acuity (BCVA)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026